Genome editing

Genome Editing



Advancing Chimeric Antigen Receptor-Engineered T-Cell Immunotherapy Using Genome Editing Technologies: Challenges and Future Prospects

Chimeric antigen receptor engineered-T (CAR-T) cells also named as living drugs, have been recently known as a breakthrough technology and were applied as an adoptive immunotherapy against different types of cancer. They also attracted widespread interest because of the success of B-cell malignancy therapy achieved by anti-CD19 CAR-T cells. Current genetic toolbox enabled the synthesis of CARs ...

Genome Editing With Targeted Deaminases

Luhan Yang, Adrian W. Briggs*, Wei Leong Chew*, Prashant Mali, Marc Guell, John Aach, Daniel Bryan Goodman, David Cox, Yinan Kan, Emal Lesha Venkataramanan Soundararajan, Feng Zhang, George Church 1 Department of Genetics, Harvard Medical School, Boston, MA 2 Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, MA 3 Harvard-MIT Division of Health Science and Technology...

Genome Editing using NucleofectorTM Technology

Genome editing using Cas9 nickases.

The RNA-guided, sequence-specific endonuclease Cas9 has been widely adopted as genome engineering tool due to its efficiency and ease of use. Derived from the microbial CRISPR (clustered regularly interspaced short palindromic repeat) type II adaptive immune system, Cas9 has now been successfully engineered for genome editing applications in a variety of animal and plant species. To reduce pote...